Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents
摘要:
New dialkylimidazole based sterol 14 alpha-demethylase inhibitors were prepared and tested as potential anti-Trypanosoma cruzi agents. Previous studies had identified compound 2 as the most potent and selective inhibitor against parasite cultures. In addition, animal studies had demonstrated that compound 2 is highly efficacious in the acute model of the disease. However, compound 2 has a high molecular weight and high hydrophobicity, issues addressed here. Systematic modifications were carried out at four positions on the scaffold and several inhibitors were identified which are highly potent (EC50 <1 nM)against T. cruzi in culture. The halogenated derivatives 36j, 36k, and 36p, display excellent activity against T. cruzi amastigotes, with reduced molecular weight and lipophilicity, and exhibit suitable physicochemical properties for an oral drug candidate. (C) 2013 Elsevier Ltd. All rights reserved.
Synthesis of Alkyl-Aryl Ethers by Copper-catalyzed Etherization Reactions of Aryl Fluorides with Tetraalkylammonium Bromides and H2O
作者:Feng Wang、Boxiao Tang、Yexiang Xie、Jinheng Li
DOI:10.1002/cjoc.201090383
日期:2010.11
Synthesis of alkyl arylethers via copper‐catalyzed etherizations of electron‐deficient aryl fluorides with quaternary ammonium bromides and water has been developed. In the presence of Cu(OAc)2, POPh3 (L4) and Cs2CO3, a variety of electron‐deficient aryl fluorides underwent the reaction with quaternary ammonium bromides and H2O in moderate to good yields. The mechanism was also discussed.
已经开发了通过缺电子的芳基氟化物与溴化季铵和水的铜催化醚化反应来合成烷基芳基醚的方法。在存在Cu(OAc)2,POPh 3(L4)和Cs 2 CO 3的情况下,各种缺电子的芳基氟化物与季铵溴化物和H 2 O反应的产率中等至良好。还讨论了该机制。
Silver-Catalyzed Arylation of (Hetero)arenes by Oxidative Decarboxylation of Aromatic Carboxylic Acids
作者:Jian Kan、Shijun Huang、Jin Lin、Min Zhang、Weiping Su
DOI:10.1002/anie.201408630
日期:2015.2.9
arylation of heteroarenes by oxidative decarboxylation of aromatic carboxylic acids. To address this challenge, the silver‐catalyzed intermolecular Minisci reaction of aromatic carboxylic acids was developed. With an inexpensive silver salt as a catalyst, this new reaction enables a variety of aromatic carboxylic acids to undergo decarboxylative coupling with electron‐deficient arenes or heteroarenes regardless
The object of the present patent application are agents for the oxidative coloring of keratin fibers, particularly hair, based on a developer-coupler combination, characterized in that they contain as the developer at least one 2,5-diamino-1-phenylbenzene derivative of general formula
and novel 2,5-diamino-1-phenylbenzene derivatives of formula (I) wherein at least one of the R1 to R10 radicals is different from hydrogen.
Mechanistically, this process capitalizes on the conversion of nitrobenzenes into the corresponding single nitrenes, which undergo a series of N-insertion, electrocyclic ring expansion, amine addition, and electrocyclic ringcontractionenroute to the ortho-phenylenediamines.
Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD
作者:R. Murray McKinnell、Uwe Klein、Martin S. Linsell、Edmund J. Moran、Matthew B. Nodwell、Juergen W. Pfeiffer、G. Roger Thomas、Cecile Yu、John R. Jacobsen
DOI:10.1016/j.bmcl.2014.04.095
日期:2014.7
A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled beta(2)-agonists. Addition of amine moieties to the neutral secondary binding group of an existing beta(2)-agonist series was found to provide improved in vivo efficacy, but also led to the formation of biologically active aldehyde metabolites which were viewed as a risk for the development of these compounds. Structural simplification of the scaffold and blocking the site of metabolism to prevent aldehyde formation afforded a potent series of dibasic beta(2)-agonists with improved duration of action relative to their monobasic analogs. Additional optimization led to the discovery of 29 (TD-4306), a potent and selective beta(2)-agonist with potential for once-daily dosing. (C) 2014 Elsevier Ltd. All rights reserved.